Influence of gastroesophageal flap valve on esophageal variceal bleeding in patients with liver cirrhosis

2020 ◽  
Vol 33 (1) ◽  
pp. 100-109
Author(s):  
Yudai Koya ◽  
Michihiko Shibata ◽  
Tatsuyuki Watanabe ◽  
Shinsuke Kumei ◽  
Koichiro Miyagawa ◽  
...  
Keyword(s):  
Liver Cirrhosis ◽  
Variceal Bleeding ◽  
Esophageal Variceal ◽  
Esophageal Variceal Bleeding ◽  
Gastroesophageal Flap Valve ◽  
Flap Valve

scholarly journals Esophageal Variceal Bleeding as the First Manifestation of COVID-19 Infection: A Case Report

2022 ◽  
Vol 7 (01) ◽  
pp. 41-45
Author(s):  
Christos Sotiropoulos, MD, MSc ◽  
Eftichia Sakka, MD ◽  
Georgios Theocharis, MD, PhD ◽  
Konstantinos Thomopoulos, MD, PhD
Keyword(s):  
Liver Cirrhosis ◽  
Case Report ◽  
Variceal Bleeding ◽  
Clinical Manifestations ◽  
Polymerase Chain Reaction Test ◽  
Variceal Hemorrhage ◽  
Esophageal Variceal ◽  
Esophageal Variceal Bleeding ◽  
Wide Range ◽  
Upper Gastrointestinal

Liver cirrhosis is a defined liver disease with a wide range of clinical manifestations. Variceal bleeding is the main source of gastrointestinal hemorrhage among cirrhotic patients induced by several factors, such as alcohol consumption or infections. This is a report of a cirrhotic patient presenting with esophageal variceal bleeding in the context of COVID-19 infection. We report the case of a 53-year-old patient with liver cirrhosis and multifocal hepatocellular carcinoma presenting with upper gastrointestinal bleeding as the first manifestation of COVID-19 infection. Upon admission, the patient had no symptoms suggestive of a respiratory tract infection or any contact with positive SARS-CoV-2 individual and upper gastrointestinal endoscopy revealed variceal hemorrhage. After a few hours the patient manifested with fever, cough and dyspnea and a SARS-CoV-2 polymerase chain reaction test obtained was positive. The patient was initially treated with endoscopic band ligation and transferred in the COVID-19 infection clinic, where after a few days of hospitalization he passed away. The devastating pandemic of coronavirus disease 2019 had altered the pathophysiology and clinical presentation of several chronic diseases. This case report suggests that coronavirus disease as a potential triggering factor of variceal bleeding.

Hemorheology in patients with liver cirrhosis: Special emphasis on its relation to severity of esophageal variceal bleeding

2006 ◽  
Vol 21 (5) ◽  
pp. 908-913 ◽  
Author(s):  
Tsu-Te Liu ◽  
Wen-Jang Wong ◽  
Ming-Chih Hou ◽  
Han-Chieh Lin ◽  
Full-Young Chang ◽  
...  
Keyword(s):  
Liver Cirrhosis ◽  
Variceal Bleeding ◽  
Esophageal Variceal ◽  
Esophageal Variceal Bleeding

scholarly journals Comparing the Effectiveness of Carvedilol and Propranolol to Prevent Reoccurrence of Esophageal Variceal Bleeding in Patients with Liver Cirrhosis.

2021 ◽  
Vol 15 (8) ◽  
pp. 2491-2493
Author(s):  
Liaqat Khurshid ◽  
Asadullah Khan ◽  
Salim Hassan ◽  
Adil Naseer Khan
Keyword(s):  
Liver Cirrhosis ◽  
Arterial Pressure ◽  
Portal Vein ◽  
Variceal Bleeding ◽  
Esophageal Variceal ◽  
Esophageal Variceal Bleeding ◽  
Portal Vein Flow ◽  
Group A ◽  
Cirrhotic Patients ◽  
Group B

Objective: To compare the efficacy of carvedilol and propranolol to prevent reoccurrence of esophageal variceal bleeding in patients with liver cirrhosis. Study Design: Place and Duration: Department of Gastroenterology and Hepatology, Ayub Teaching Hospital, Abbottabad, Pakistan for six months duration from 15th November 2020 to 15th May 2021. Methods: Total one hundred and forty patients of ages between 18-65 years were presented in this study. Patients detailed demographics age, sex, body mass index and Child-Turcotte-Pugh (CTP) class were recorded after taking written informed consent. Patients were equally (n=70) divided into two groups. Group A had 70 patients and received carvedilol while group B had 70 patients and received propranolol for 6 months. Reoccurrence ofesophageal variceal bleeding in cirrhotic patients among both groups were observed at 2nd, 4th and 6th months and patients pulse rate, arterial pressure and portal vein flow were recorded at these time points. Complete data was analyzed by SPSS 26.0 version. Results: Mean age of the patients in group A was 40.38 ± 5.87 years with mean BMI 28.09 ± 7.33 kg/m2 and in group B mean age was 39.43 ± 12.69 years with mean BMI 27.53 ± 8.84 kg/m2. In group A 45 (64.3%) patients were males and 25 (35.7%) were female patients while in group B 50 (71.43%) were male patients and 20 (28.7%) patients were females. We found that there was no statistically significant difference observed among both groups regarding these demographic variables. Reoccurrence of bleeding observed in group A was significantly lower (among 20 (28.6%) cases) as compared to group B (among 36 (51.43%) cases). Pulse rate, mean arterial pressure and portal vein flow was found lower in the carvedilol group as compared to propanol group with p value < 0.05 upon follow up at2,4 and 6 months. Conclusion: We found in this study that the drug carvedilol was more effective and safe to prevent reoccurrence of esophageal variceal bleeding in cirrhotic patients as compared to propanol. Keywords: Cirrhotic patients, Carvedilol, Propanol, Portal vein flow, Mean arterial pressure

Sign in / Sign up

Export Citation Format

Share Document